What is Bafna Pharmaceuticals Ltd. Quarterly Revenue?

Bafna Pharmaceuticals Ltd. Quarterly Revenue Bafna Pharma Jun-2026 Quarterly Revenue is Rs 28 Cr which is growth of -19.1% YoY.

What is Bafna Pharmaceuticals Ltd. Quarterly Net Profit?

Bafna Pharmaceuticals Ltd. Quarterly Net Profit Bafna Pharma Jun-2026 Quarterly Net Profit is Rs 0 Cr which is growth of -97.8% YoY.

What is Bafna Pharmaceuticals Ltd. Annual Revenue?

Bafna Pharmaceuticals Ltd. Annual Revenue Bafna Pharma Mar-2026 Annual Revenue is Rs 155 Cr which is growth of 4.6% YoY.

What is Bafna Pharmaceuticals Ltd. Annual Net Profit?

Bafna Pharmaceuticals Ltd. Annual Net Profit Bafna Pharma Mar-2026 Annual Net Profit is Rs 11 Cr which is growth of 167.3% YoY.

What is Bafna Pharmaceuticals Ltd. Total Shareholders Fund?

Bafna Pharmaceuticals Ltd. Total Shareholders Fund Bafna Pharma Mar-2026 Total Shareholders Fund is Rs 96 Cr which is growth of 13.4% YoY.

What is Bafna Pharmaceuticals Ltd. Total Assets?

Bafna Pharmaceuticals Ltd. Total Assets Bafna Pharma Mar-2026 Total Assets is Rs 176 Cr which is growth of 14.7% YoY.

What is Bafna Pharmaceuticals Ltd. Book Value Per Share?

Bafna Pharmaceuticals Ltd. Book Value Per Share Bafna Pharma Mar-2026 Book Value Per Share is 41 Rs which is growth of 13.4% YoY.

What is Bafna Pharmaceuticals Ltd. ROE?

Bafna Pharmaceuticals Ltd. ROE Bafna Pharma Mar-2026 ROE is 12% which is growth of 6.6% YoY.

What is Bafna Pharmaceuticals Ltd. Cash From Operating Activity?

Bafna Pharmaceuticals Ltd. Cash From Operating Activity Bafna Pharma Mar-2026 Cash From Operating Activity is Rs 15 Cr which is growth of -30.6% YoY.

What is Bafna Pharmaceuticals Ltd. Net Cash Flow?

Bafna Pharmaceuticals Ltd. Net Cash Flow Bafna Pharma Mar-2026 Net Cash Flow is Rs -1 Cr which is growth of -169.1% YoY.

Bafna Pharmaceuticals Ltd.

NSE: BAFNAPH | BSE: 532989

Expensive Star

Download real time

6.55(1.99%)

New 52W High today

2,444

NSE+BSE Volume

NSE 23 Sep, 2026 11:44 AM (IST)

Portfolio

Alert

My Notes

Bafna Pharma quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Bafna Pharma quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

NEGATIVE
Quarterly Revenue Bafna Pharma Jun-2026 Quarterly Revenue is Rs 28 Cr which is growth of -19.1% YoY.
NEGATIVE
Quarterly Net Profit Bafna Pharma Jun-2026 Quarterly Net Profit is Rs 0 Cr which is growth of -97.8% YoY.

Bafna Pharmaceuticals Ltd., Quarterly, standalone, All financials are in INR Cr and price data in INR
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
TOTAL_SR_Q Total Rev. ⌄	28.5	44	39.5	36.7	35.2	40.1	33.4	41.4	33.8	41.9	29.4	40.8	43.8
SR_Q Operating Rev.	26.6	42.2	38.3	35.5	34.6	39.1	33.2	40.3	33.3	41.4	28.4	40.7	42
OI_Q Other Income	1.9	1.8	1.2	1.2	0.6	1	0.2	1	0.5	0.5	1	0.2	1.9
OEXPNS_Q Operating Exp.	25.7	38.7	35.2	31.2	29.6	36	30.1	36.5	32.1	38.5	30.5	36.7	35.7
OEXPNS_Q Operating Exp.	25.7	38.7	35.2	31.2	29.6	36	30.1	36.5	32.1	38.5	30.5	36.7	35.7
OP_Q Operating Profit	0.9	3.6	3.1	4.3	5.1	3.1	3.1	3.8	1.2	2.9	-2.1	4	6.3
OPMPCT_Q Operating Profit Margin %	3.32%	8.40%	7.97%	12.07%	14.64%	7.97%	9.22%	9.41%	3.64%	6.97%	-7.30%	9.84%	15.01%
DEP_Q Depr.	1.8	1.7	1.6	1.5	1.4	0.2	1.7	1.6	1.4	1.3	1.3	1.2	1.2
INT_Q Interest	0.9	1	0.9	0.9	0.9	0.8	0.6	0.6	0.7	0.7	0.6	0.4	0.6
PBT_Q Profit Before Tax	0.1	2.6	1.8	3.1	3.4	1.3	1	2.6	-0.7	1.5	-2.9	2.5	6.4
TAX_Q Tax		-0.1
NP_Q Net Profit	0.1	2.8	1.8	3.1	3.4	1.3	1	2.6	-0.7	1.5	-2.9	2.5	6.4
EPS_adj_Q EPS Adj. latest	0	1.2	0.8	1.3	1.4	0.6	0.4	1.1	-0.3	0.6	-1.2	1.1	2.7
NP_TTM Net profit TTM	7.8	11.1	9.7	8.8	8.3	4.2	4.3	0.4	0.3	7.4	11.3	17.2	16.3
EPS_TTM Basic EPS TTM	3.3	4.7	4.1	3.7	3.5	1.8	1.8	0.2	0.1	3.1	4.8	7.3	6.9
results_pdf Results PDF
result_notes Result Notes	Notes	Notes	Notes	Notes	Notes		Notes	Notes			Notes		Notes

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Bafna Pharma competitor comparison and performance snapshot within industry

Bafna Pharma annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue Bafna Pharma Mar-2026 Annual Revenue is Rs 155 Cr which is growth of 4.6% YoY.
POSITIVE
Annual Net Profit Bafna Pharma Mar-2026 Annual Net Profit is Rs 11 Cr which is growth of 167.3% YoY.

Bafna Pharmaceuticals Ltd., Annual, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
SR_A Total Rev. Ann. ⌄	9.4%	16.6%	148.6	155.4	148.6	156	118.6	87.2	72	42.7	44	78.4	66.1	86.6
TotalOperatingRevenues_A Operating Rev. Ann.	9.3%	16.2%	142.6	150.6	145.9	152.5	115.4	85.1	71.2	42.5	43.4	47.2	65	85.3
OI_A Other Income Ann.	13.3%	43.1%	6.1	4.8	2.7	3.5	3.3	2.1	0.8	0.3	0.7	31.3	1.1	1.2
OEXPNS_A Operating Exp. Ann.	10.6%	17.2%	130.8	134.7	134.7	141.4	99.6	73.7	60.9	41.2	56.7	82.3	70.2	82.5
OEXPNS_A Operating Exp. Ann.	10.6%	17.2%	130.8	134.7	134.7	141.4	99.6	73.7	60.9	41.2	56.7	82.3	70.2	82.5
OP_A Operating Profit Ann.	0.6%	9.2%	11.8	16	11.2	11.1	15.7	11.5	10.3	1.2	-13.3	-35.1	-5.2	2.8
OPMPCT_A OPM Ann. %	-8.2%	-6.4%		10.26%	7.52%	7.12%	13.25%	13.17%	14.31%	2.88%	-30.30%	-44.74%	-7.89%	3.25%
TotalExpenses_A Total Exp. Ann. ⌄	10.5%	16.9%		144.4	142.3	148.6	107	79.9	66.1	44.6	62.2	92.7	85.4	99.1
OtherExpenses_A Other Exp. Ann.	12.7%	24.1%	31.7	10.3	10.6	15.4	7.2	7.9	3.5	4	13.1	30.9	6.1	4.8
EmployeeBenefitExpenses_A Employee Exp. Ann.	11.3%	12.8%	21.9	21.9	21	19	15.9	14.5	12	10.3	9	7.5	6.6	6.4
CostOfPowerPurchased_A Cost Of Power Purchased Ann.	-	-
CostOfFuel_A Cost Of Fuel Ann.	-	-
EBIDT_A EBITDA Ann.	2.9%	13.3%		20.7	13.9	14.6	19	13.6	11.1	1.5	-12.7	-3.8	-4.1	4.1
EBIDTPCT_A EBITDA Ann. margin %	-5.9%	-2.8%		13.33%	9.37%	9.38%	16.01%	15.58%	15.35%	3.47%	-28.81%	-4.88%	-6.17%	4.69%
INT_A Interest Ann.	22.8%	39.5%	3.7	3.7	2.7	2.3	2	0.8	0.7	0.1	2.1	6.8	11.3	12.5
DEP_A Depr.	4.8%	6.3%	6.5	6.1	4.9	5	5.3	5.5	4.5	3.3	3.4	3.7	3.9	4.1
PBT_A PBT Ann.	-1.8%	13.7%	7.7	11	4.2	7.4	11.6	5.2	5.8	-25.2	-18.2	-14.3	-19.3	-12.5
TAX_A Tax Ann.	-	-	-0.1	-0.1			0.3				1.5	2.2	-0.8	-0.3
PAT_A PAT Before ExtraOrdinary Items Ann. ⌄	-0.6%	13.9%		11.1	4.2	7.4	11.3	5.2	5.8	-25.2	-19.7	-16.5	-18.5	-12.2
IncomeMinorityInterest_A Minority Interest Income Ann.	-	-		-	-	-	-	-	-	-	-	-	-	-
NP_A Net Profit Ann.	-0.6%	13.9%	7.8	11.1	4.2	7.4	11.3	5.2	5.8	-25.2	-19.7	-16.5	-18.5	-12.2
NETPCT_A NPM Ann. %	-9.2%	-2.1%		7.36%	2.84%	4.81%	9.82%	6.05%	8.18%	-59.34%	-45.50%	-34.87%	-28.43%	-14.28%
EPS_adj_A EPS Adj. latest Ann.	-0.7%	13.5%		4.7	1.8	3.1	4.8	2.2	2.5	-10.7	-8.3	-7	-7.8	-5.2
result_notes Result Notes				Notes			Notes	Notes	Notes	Notes	Notes	Notes	Notes
Annual_Reports Annual Reports

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Total Rev. Ann.

1Y CHG

4.6%

2Y CAGR

-0.2%

3Y CAGR

9.4%

5Y CAGR

16.6%

7Y CAGR

19.8%

10Y CAGR

Total Revenue Annual growth is lower than historical averages.

Net Profit Ann.

1Y CHG

164.3%

2Y CAGR

22.5%

3Y CAGR

-0.6%

5Y CAGR

13.9%

Net Profit Annual growth is stable compared to historical averages.

Operating Exp. Ann.

2Y CAGR

-2.4%

3Y CAGR

10.6%

5Y CAGR

17.2%

7Y CAGR

13.2%

10Y CAGR

Operating Expenses Annual Cr is falling faster than historical averages.

Bafna Pharma balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Total Shareholders Fund Bafna Pharma Mar-2026 Total Shareholders Fund is Rs 96 Cr which is growth of 13.4% YoY.
POSITIVE
Total Assets Bafna Pharma Mar-2026 Total Assets is Rs 176 Cr which is growth of 14.7% YoY.

Bafna Pharmaceuticals Ltd., Balance Sheet, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	9.4%	11.1%	96.2	84.8	80.8	73.5	62.9	56.8	-4.4	20.8	40.5	45	59.4
EQCAP_A Equity Share Capital Ann.	0%	0%	23.7	23.7	23.7	23.7	23.7	23.7	2.4	23.7	23.7	18.7	18.7
TotalShareCapital_A Total Share Capital Ann.	0%	0%	23.7	23.7	23.7	23.7	23.7	23.7	2.4	23.7	23.7	18.7	18.7
ReservesAndSurplus_A Reserves Plus Surplus Ann.	13.3%	17%	72.5	61.2	57.2	49.8	39.2	33.1	-6.8	-2.9	16.9	22.3	40.8
TotalReservesAndSurplus_A Total Reserves Plus Surplus Ann.	13.3%	17%	72.5	61.2	57.2	49.8	39.2	33.1	-6.8	-2.9	16.9	22.3	40.8
LiabilityMinorityInterest_A Minority Interest Liability Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann. ⌄	31.8%	32.7%	22.2	16.4	12.8	9.7	11	5.4	3	29.2	28	41.5	38.5
DeferredTaxLiabilities_A Deferred Tax Liabilities Ann.	-	-								6.2	4.7	2.5	3.3
OtherLongTermLiabilities_A Other LongTerm Liabilities Ann.	49.4%	6.6%	4	1.9	1.6	1.2	3.1	2.9		0	0	0	0
CL_A Total Current Liabilities Ann. ⌄	7.1%	18.7%	57.2	51.9	54.1	46.5	16.4	24.3	17.1	70.7	59	80.6	87
TradePayables_A Trade Payables Ann.	3.2%	23.9%	31.3	31	35.4	28.5	12.4	10.7	12.5	39.4	27.8	23.4	29.9
OtherCurrentLiabilities_A Other Current Liabilities Ann.	18.3%	-18.8%	4.8	5.4	3.8	2.9	4	13.6	4.6	8	7.9	13.9	11.7
ShortTermProvisions_A ST Provisions Ann.	35.7%	-	1.5	1.4	1.3	0.6
TL_A Total Capital Plus Liabilities Ann.	10.6%	15.2%	175.5	153.1	147.7	129.6	90.2	86.5	71.1	120.6	127.5	167.2	184.9
FixedAssets_A Fixed Assets Ann. ⌄	26.7%	18.2%	84.9	66.1	52.5	41.7	38.9	36.8	35.2	37	39.9	43.3	47
TangibleAssets_A Tangible Assets Ann.	26.7%	17.8%	81.8	58.8	40.2	40.2	38.9	36	35	37	39.9	43.3	47
IntangibleAssets_A Intangible Assets Ann.	-	-
CapitalWorkInProgress_A Capital Work In Progress Ann.	-	31.1%	3.1	7.3	10.5			0.8	0.2
TotalNonCurrentAssets_A Total Non Current Assets Ann. ⌄	26.6%	18.5%	85.9	66.9	53.2	42.3	38.9	36.8	35.2	72.4	79.2	90.3	66
NonCurrentInvestments_A Non Current Investments Ann.	-	-								1.4	1.4	18.3	18.3
DeferredTaxAssets_A Deferred Tax Assets Ann.	-	-
LongTermLoansAndAdvances_A LT Loans Plus Advances Ann.	-	-
OtherNonCurrentAssets_A Other Non Current Assets Ann.	26%	-	1	0.8	0.7	0.5				34	37.9	28.7	0.7
CA_A Total Current Assets Ann. ⌄	0.9%	12.5%	89.7	86.2	94.5	87.3	51.4	49.7	35.9	48.2	48.3	76.9	118.9
CurrentInvestments_A Current Investments Ann.	-	-
TradeReceivables_A Trade Receivables Ann.	2.1%	35.5%	43.9	40.2	45.4	41.2	14.8	9.6	6	24.8	24.3	53.7	80.8
CashAndCashEquivalents_A Cash Plus Cash Equivalents Ann.	-36.5%	2.1%	2	3.4	1.4	7.8	0.2	1.8	8.5	2.7	2.7	2.7	2.7
ShortTermLoansAndAdvances_A ST Loans Plus Advances Ann.	0%	-	0.1	0	0.1	0.1							19.1
OtherCurrentAssets_A Other Current Assets Ann.	-3%	-8.5%	14.7	14.5	18	16.1	16.2	22.9	10	11.4	10.6	3.8
TA_A Total Assets Ann.	10.6%	15.2%	175.5	153.1	147.7	129.6	90.2	86.5	71.1	120.6	127.5	167.2	184.9
ContingentLiabilities_A Contingent Liabilities plus Commitments Ann.	-0.6%	-	10.3	10.7	10.8	10.5	2.4				0.5	0.3	1.6
BonusEquityShareCapital_A Bonus Equity Share Capital Ann.	0%	0%	0.5	0.5	0.5	0.5	0.5	0.5	0.5	5.4	5.4	5.4	5.4
NonCurrentInvestmentsUnquotedBookValue_A Non Current Investments Unquoted Book Value Ann.	-	-								1.4	1.4	18.3	1.4
CurrentInvestmentsUnquotedBookValue_A Current Investments Unquoted Book Value Ann.	-	-

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Total Assets Ann.

1Y CHG

14.6%

2Y CAGR

3Y CAGR

10.6%

5Y CAGR

15.2%

7Y CAGR

5.5%

10Y CAGR

-0.5%

Total Assets Annual growth is stable compared to historical averages.

Total Current Liabilities Ann.

1Y CHG

10.2%

2Y CAGR

2.8%

3Y CAGR

7.1%

5Y CAGR

18.7%

7Y CAGR

-3%

10Y CAGR

-4.1%

Total Current Liabilities Annual Cr growth is stable compared to historical averages.

Total ShareHolders Funds Ann.

1Y CHG

13.4%

2Y CAGR

9.1%

3Y CAGR

9.4%

5Y CAGR

11.1%

7Y CAGR

24.5%

10Y CAGR

4.9%

Total ShareHolders Funds Annual growth is stable compared to historical averages.

Bafna Pharma ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Book Value Per Share Bafna Pharma Mar-2026 Book Value Per Share is 41 Rs which is growth of 13.4% YoY.
POSITIVE
ROE Bafna Pharma Mar-2026 ROE is 12% which is growth of 6.6% YoY.

Bafna Pharmaceuticals Ltd., Ratios, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
BVSH_A BVSH Ann.	9.3%	11.1%	40.6	35.9	34.2	31.1	26.6	24	-18.6	8.8	17.1	24.1	31.9
ROA_A RoA Ann. %	-10.2%	-1.2%	6.32%	2.71%	4.97%	8.74%	5.70%	6.73%	-35.46%	-16.35%	-12.90%	-11.04%	-6.58%
ROE_A ROE Ann. %	-9.2%	2.4%	11.54%	4.89%	9.08%	15.43%	8.19%	10.26%		-94.88%	-40.59%	-41.06%	-20.49%
ROCE_A ROCE Ann. %	-9%	3.2%	12.36%	8.91%	10.29%	16.42%	10.96%	10.56%	-3.30%	-32.21%	-10.90%	-9.21%	-0.05%
ProfitabilityHeader Profitability Ratio ⌄
PBDITMargin_A EBITDA Ann. Margin %	-5.8%	-2.4%	13.74%	9.54%	9.59%	16.46%	15.96%	15.51%	3.49%	-29.24%	-8.10%	-6.27%	4.75%
PBITMargin_A EBIT Ann. Margin %	-6.4%	1%	9.71%	6.19%	6.32%	11.83%	9.51%	9.22%	-4.19%	-37.13%	-15.83%	-12.26%	-0.06%
PBTMargin_A PBT Ann. Margin %	-10.3%	-2.3%	7.28%	2.84%	4.81%	10.07%	6.05%	8.18%	-59.34%	-42.04%	-30.26%	-29.71%	-14.68%
NETPCT_A NPM Ann. %	-9.2%	-2.1%	7.36%	2.84%	4.81%	9.82%	6.05%	8.18%	-59.34%	-45.50%	-34.87%	-28.43%	-14.28%
ASETTO_A Asset Turnover Ann. %	-6.5%	0%	0.9	1	1.1	1.1	1	0.9	0.4	0.4	0.3	0.4	0.5
LiquidityHeader Liquidity Ratio ⌄
CRATIO_A Current Ratio Ann.	-5.6%	-4.4%	1.6	1.7	1.8	1.9	3.1	2	2.1	0.7	0.8	1	1.4
QuickRatio_A Quick Ratio Ann.	-7.7%	-4.7%	1.1	1.1	1.2	1.4	1.9	1.4	1.4	0.6	0.6	0.8	1.2
DividendPayoutNP_A Dividend Payout to NP Ann.	-	-
EarningRetention_A Earning Retention Ann. %	-	-
CashEarningRetention_A Cash Earning Retention Ann. %	-	-
CashEarningRetention_A Cash Earning Retention Ann. %	-	-
ValuationHeader Valuation Ratio ⌄
EnterpriseValue_A EnterpriseValue Ann.	12.9%	-1.4%	302.7	202.2	204.3	210.6	308.2	325.5	-3.4	69.4	110.1	134.9	133.6
EVPerNetSales_A EV Per Net Sales Ann.	3.6%	-15.3%	2	1.4	1.3	1.8	3.6	4.6	-0.1	1.6	2.3	2.1	1.6
PBV_A Price To Book Value Adjusted	-8.6%	-10%	8.28	9.39	9.85	10.84	12.66	14.02	-18.05	38.29	19.64	13.96	10.56
EVPerEBITDA_A EV Per EBITDA Ann.	9.6%	-13.1%	14.6	14.5	14	11.1	22.7	29.5	-2.3	-5.5	-28.8	-33.1	32.9
MarketCapPerSales_A Market Cap Per Sales Ann.	1.9%	-17.1%	1.8	1.2	1.2	1.7	3.5	4.6	0.1	0.6	1.4	0.9	0.7
RetentionRatios_A Retention Ratio Ann. %	-	-
EYield_A Earnings Yield Ann.	-	-	0	0	0	0.1	0	0	-12	-0.8	-0.3	-0.3	-0.2
DEBT_CE_A Total Debt to Total Equity Ann.	10.1%	-	0.4	0.3	0.3	0.3	0.1	0	-0.7	2.2	1.2	1.8	1.4

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

ROE Ann. %

1Y CHG

136%

2Y CAGR

12.7%

3Y CAGR

-9.2%

5Y CAGR

2.4%

ROE Annual % is stable compared to historical averages.

RoA Ann. %

1Y CHG

133.2%

2Y CAGR

12.8%

3Y CAGR

-10.2%

5Y CAGR

-1.2%

RoA Annual % is stable compared to historical averages.

Current Ratio Ann.

1Y CHG

-5.9%

2Y CAGR

-5.7%

3Y CAGR

-5.6%

5Y CAGR

-4.4%

7Y CAGR

12.5%

10Y CAGR

1.3%

Current Ratio Annual is falling faster than historical averages.

Bafna Pharma cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Cash From Operating Activity Bafna Pharma Mar-2026 Cash From Operating Activity is Rs 15 Cr which is growth of -30.6% YoY.
NEGATIVE
Net Cash Flow Bafna Pharma Mar-2026 Net Cash Flow is Rs -1 Cr which is growth of -169.1% YoY.

Bafna Pharmaceuticals Ltd., Cash Flow, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
CFO_A Cash from Operating Act. Ann. ⌄	45.5%	-	15.4	22.1	9.5	5	8	-13.6	-34.3	-1.1	-7.1	19.8	-3
PBT_A PBT Ann.	-1.8%	13.7%	11	4.2	7.4	11.6	5.2	5.8	-25.2	-18.2	-14.3	-19.3	-12.5
INT_A Interest Ann.	22.8%	39.5%	3.7	2.7	2.3	2	0.8	0.7	0.1	2.1	6.8	11.3	12.5
TAX_A Tax Ann.	-	-	-0.1			0.3				1.5	2.2	-0.8	-0.3
CFI_A Cash from Investing Act. Ann.	-	-	-22.4	-21.2	-15.1	-7.5	-5.4	-5.4	32.8	3.5	37.8	-14.4	-1.1
CFA_A Cash from Financing Act. Ann.	-18.1%	-14.6%	5.6	1.1	-0.9	10.2	-4.2	12.3	7.3	-2.4	-30.7	-5.4	4.3
NCF_A Net Cash Flow Ann. ⌄	-	-	-1.4	2	-6.4	7.6	-1.6	-6.7	5.8		0.1	-0	0.3
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	157.1%	-16.7%	3.4	1.4	7.8	0.2	1.8	8.5	2.7	2.7	2.7	2.7	2.5
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	-36.5%	2.1%	2	3.4	1.4	7.8	0.2	1.8	8.5	2.7	2.7	2.7	2.7

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Cash from Operating Act. Ann.

1Y CHG

-30.3%

2Y CAGR

27.3%

3Y CAGR

45.5%

Cash from Operating Activity Annual is falling faster than historical averages.

Cash from Financing Act. Ann.

1Y CHG

409.1%

3Y CAGR

-18.1%

5Y CAGR

-14.6%

10Y CAGR

2.7%

Cash from Financing Annual Activity growth is higher than historical averages.

Bafna Pharma investor presentations, annual reports, credit ratings, and earnings calls with AI summary, video, and audio access

Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow
Documents

New 52W High today

Bafna Pharma quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents